Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice
Laquente, Berta (Hospital Duran i Reynals (Hospitalet del Llobregat))
Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia)
Bugés, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Martín, Marta (Institut d'Investigació Biomèdica Sant Pau)
García, Carlos (Complejo Hospitalario de Burgos)
Pericay, Carles (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Merino, Sandra (Hospital Universitari Sant Joan de Reus (Tarragona))
Visa, Laura (Hospital del Mar (Barcelona, Catalunya))
Martín, Teresa (Hospital Universitario de Salamanca)
Pedraza, Manuela (Complejo Asistencial Universitario de León)
Carnero, Beatriz (Hospital El Bierzo)
Guardeño, Raquel (Institut Català d'Oncologia)
Verdaguer, Helena (Vall d'Hebron Institut d'Oncologia)
Mut, Alejandro (Celgene S.L.U)
Vilanova, David (Celgene S.L.U)
García, Adelaida (Institut Català d'Oncologia)
Universitat Autònoma de Barcelona

Fecha:	2020
Resumen:	Despite advances in surgery, radiotherapy, and chemotherapy, pancreatic adenocarcinoma often progresses rapidly and causes death. The physical decline of these patients is expected to impact their quality of life (QoL). Therefore, in addition to objective measures of effectiveness, the evaluation of health-related QoL should be considered a matter of major concern when assessing therapy outcomes. Observational, prospective, multicenter study including patients with metastatic pancreatic adenocarcinoma who started first-line chemotherapy in 12 Spanish centers. Treatment and clinical characteristics were recorded at baseline. Patients' health-related quality of life, ECOG, and Karnofsky index were measured at baseline, at Days 15 and 30, and every four weeks up to 6 months of chemotherapy. Health-related quality of life was measured using the EORTC-QLQ-C30 and EQ-5D questionnaires. Other endpoints included overall survival and progression-free survival. The study sample included 116 patients (median age of 65 years). Mean (SD) scores for the QLQ-C30 global health status scale showed a significant increasing trend throughout the treatment (p = 0. 005). Patients with either a Karnofsky index of 70-80 or ECOG 2 showed greater improvement in the QLQ-C30 global health status score than the corresponding groups with better performance status (p ≤ 0. 010). Pain, appetite, sleep disturbance, nausea, and constipation significantly improved throughout the treatment (p < 0. 005). Patients with QLQ-C30 global health status scores ≥50 at baseline had significantly greater overall survival and progression-free survival (p = 0. 005 and p = 0. 021, respectively). No significant associations were observed regarding the EQ-5D score. Most metastatic pancreatic adenocarcinoma patients receiving first-line chemotherapy showed an increase in health-related quality of life scores throughout the treatment. Patients with lower performance status and health-related quality of life at baseline tended to greater improvement. The EORTC QLQ-C30 scale allowed us to measure the health-related quality of life of metastatic pancreatic adenocarcinoma patients receiving first-line chemotherapy.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Cancer chemotherapy ; EORTC QLQ-C30 ; Health-related quality of life ; Pancreatic Cancer ; Performance status
Publicado en:	BMC Palliative Care, Vol. 19 Núm. 1 (october 2020) , p. 610, ISSN 1472-684X

DOI: 10.1186/s12904-020-00610-4
PMID: 32650765

11 p, 1.9 MB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Instituto de Investigación e Innovación Parc Taulí (I3PT)
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados